Correction

New therapeutics, technologies help clinicians fight dry eye,” in the February 2019 issue, should have said that Oyster Point is developing two drug candidates – both delivered via a nasal spray – to determine which compound may offer a better safety and efficacy profile and increase the likelihood of regulatory and commercial success.

New therapeutics, technologies help clinicians fight dry eye,” in the February 2019 issue, should have said that Oyster Point is developing two drug candidates – both delivered via a nasal spray – to determine which compound may offer a better safety and efficacy profile and increase the likelihood of regulatory and commercial success.